The first publication regarding rationale and study design of GRECCO-19 is online in Hellenic Journal of Cardiology (Elsevier). Potential pathophysiologic mechanisms are also described.
It is a well-known drug with anti-inflammatory properties, used to treat many diseases – Submitted by research team at EODY
Long research group led by Professor Cardiology n. Spiro Deftereos, filed research proposal to PHEA on the use of a known drug, colchicine for the treatment of patients from disease coronavirus (COVID-19).
The research protocol involves a large number of distinguished Greek and foreign scientists, from the field of Infectious Diseases, Cardiology, Epidemiology, Pulmonology and Intensive Care, as shown below:
GRECCO-19 study (The Greek study of the effects of Colchicine in Covid-19 complications prevention)
Spyridon C. Deftereos, Gerasimos LEFKOSIA Georgios Giannopoulos Dimitrios A.. Vrahatis Christos Angelides Salvation III. Giotaki Panagiotis Gargalianos Helen Giamarellou Charalambos Gogos Georgios Saiki, Marios lasagne, Pagona Lagiou, George Saroglou Nikolaos Sypsas, Sotirios Tsiodras , Dimitrios Hatzigeorgiou, Nikolaos Moussas, Anastasia Kotanidou, Nikolaos Koulouris, Evangelos Ikonomou, Andreas Koukis, Charalambos Kosivakis, Konstantinos Raisakis, Katerina Fountoulis, Michiris Echmiakis We, Luis Martinez-Dolz, Sanz-Sánchez Jorge, Bernhard Reimers, Giulio G. Stefanini, Michael Cleman, Dimitrios Filippou, Christopher D. Olympios, Vlasios N. Pyrgakis, Ioannis Goudevenos, Georgios Chachalis, Theophilos Itholis, Theofilos Ioannis. Dimitrios Tousoulis, Christodoulos Stefanadis.
Department of Cardiovascular Medicine – Yale University, USA
Responsible: Prof. Michael Cleman
Department of Cardiovascular Medicine, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
Managers: Dr. Bernhard Reimers (Director), Prof. Giulio Stefanini
Cardiology Department, Hospital Universitario y Politécnico La Fe University of Valencia. Valencia (Spain)
Responsible: Luis Martinez Dolz MD, PhD, FESC (Director, Ass. Prof)
Colchicine is a well-known drug with anti-inflammatory and other unique properties, used to treat many diseases, such as gout, Mediterranean fever, pericarditis and others.
Over the past 10 years, S. Deuteraios, H. Stefanadis and M. Cleman (from Yale University) have expanded the indications and used colchicine successfully in the treatment of atrial fibrillation, acute myocardial infarction, and in the treatment of stenting , publishing research results in top international scientific journals.
This research protocol has been unanimously approved by the relevant EODY committee, and the clinical trial will begin immediately.
The seriousness of the hypothesis that colchicine is likely to have a positive therapeutic effect in patients with coronavirus (COVID 19) is strongly supported by the fact that after the Greek research team, and a Canadian research team, are preparing to administer the drug to 6,000 people positive for the virus, having announced a protocol.